David A Brenner
Overview
Explore the profile of David A Brenner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
279
Citations
23369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim H, Mizrahi O, Lee W, Rosenthal S, Han C, Yee B, et al.
bioRxiv
. 2025 Jan;
PMID: 39868246
Highlights: LARP6 is upregulated in liver fibrosis, mainly in HSCs.LARP6 knockdown in human HSCs reduces liver fibrosis development.Of the hundreds of gene targets, LARP6 interacts most with collagen mRNAs.LARP6 regulates...
2.
Joshi V, Carter D, Chen A, Murphy K, Higgins J, Gurel M, et al.
PLoS One
. 2025 Jan;
19(12):e0312615.
PMID: 39775546
Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (MASH), is a major risk factor for cirrhosis and hepatocellular carcinoma (HCC) and a leading cause of liver transplantation. MASH is...
3.
Cong M, Carvalho Gontijo Weber R, Sakane S, Zhang V, Jiang C, Taura K, et al.
Hepatol Commun
. 2025 Jan;
8(11).
PMID: 39761005
Background: Liver fibrosis is caused by chronic toxic or cholestatic liver injury. Fibrosis results from the recruitment of myeloid cells into the injured liver, the release of inflammatory and fibrogenic...
4.
Kim H, Rosenthal S, Liu X, Miciano C, Hou X, Miller M, et al.
J Hepatol
. 2024 Nov;
PMID: 39522884
Background & Aims: Metabolic dysfunction-associated steatotic liver disease ranges from metabolic dysfunction-associated steatotic liver (MASL) to metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. Transdifferentiation of hepatic stellate cells (HSCs) into fibrogenic...
5.
Suri A, Zhang Z, Neuschwander-Tetri B, Lomas D, Heyer-Chauhan N, Burling K, et al.
Liver Int
. 2024 Sep;
44(12):3204-3213.
PMID: 39263815
Background And Aims: The course of adults with ZZ alpha-1-antitrypsin deficiency (AATD) liver disease is unpredictable. The utility of markers, including liver biopsy, is undefined. Methods: A prospective cohort, including...
6.
Jeelani I, Moon J, da Cunha F, Nasamran C, Jeon S, Zhang X, et al.
Sci Transl Med
. 2024 Sep;
16(764):eadi0284.
PMID: 39259813
Proinflammatory hepatic macrophage activation plays a key role in the development of nonalcoholic steatohepatitis (NASH). This involves increased embryonic hepatic Kupffer cell (KC) death, facilitating the replacement of KCs with...
7.
Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2
Ganguly S, Rosenthal S, Ishizuka K, Troutman T, Rohm T, Khader N, et al.
Proc Natl Acad Sci U S A
. 2024 Aug;
121(35):e2405746121.
PMID: 39172787
While macrophage heterogeneity during metabolic dysfunction-associated steatohepatitis (MASH) has been described, the fate of these macrophages during MASH regression is poorly understood. Comparing macrophage heterogeneity during MASH progression vs regression,...
8.
Kim H, Lee W, Liu X, Jang H, Sakane S, Carvalho-Gontijo Weber R, et al.
STAR Protoc
. 2024 Jun;
5(2):103111.
PMID: 38833372
Currently, there is no effective treatment for obesity and alcohol-associated liver diseases, partially due to the lack of translational human models. Here, we present a protocol to generate 3D human...
9.
Osna N, Tikhanovich I, Ortega-Ribera M, Mueller S, Zheng C, Mueller J, et al.
Biomolecules
. 2024 Apr;
14(4.
PMID: 38672422
Alcohol-associated liver disease (ALD) is a substantial cause of morbidity and mortality worldwide and represents a spectrum of liver injury beginning with hepatic steatosis (fatty liver) progressing to inflammation and...
10.
Tan P, Ostertag T, Rosenthal S, Chilin-Fuentes D, Aidnik H, Linker S, et al.
Am J Pathol
. 2023 Dec;
194(3):353-368.
PMID: 38158078
Nonalcoholic steatohepatitis (NASH) is an inflammatory and fibrotic liver disease that has reached epidemic proportions and has no approved pharmacologic therapies. Research and drug development efforts are hampered by inadequate...